靶向抑制肝源性AGT抗高血压研究进展  

Research progress in the antihypertensive effect of targeted inhibition of hepatogenic AGT

作　　者：俞水晴 杨秀红 史国辉 YU Shuiqing;YANG Xiuhong;SHI Guohui(Department of Nephrology,North China University of Science and Technology Affiliated Hospital,Tangshan 063009,China;Department of Physiology,School of Basic Medical Sciences,North China University of Science and Technology,Tangshan 063509,China)

机构地区：[1]华北理工大学附属医院肾内科,河北唐山063000 [2]华北理工大学基础医学院生理学系,河北唐山063210

出　　处：《空军军医大学学报》2023年第8期779-785,共7页Journal of Air Force Medical University

基　　金：国家自然科学基金(81970359,81372029)。

摘　　要：肾素-血管紧张素系统(RAS)在高血压发生发展中起重要作用,血管紧张素原(AGT)是该系统惟一底物。随着RNA干扰及基因编辑技术进步,抑制肝源性AGT展现出良好的临床前景,可持续平稳降压,并改善高血压靶器官结构和功能。本文结合最新研究,对AGT基因结构及其作用,抑制肝源性AGT方法分类,抑制肝源性AGT对RAS分子、高血压及靶器官影响等方面进行阐述,为抑制肝源性AGT抗高血压治疗研究提供参考。Renin-angiotensin system(RAS)plays an important role in the development of hypertension,and angiotensinogen(AGT)is the sole substrate of this system.With the advance of RNA interference and gene editing technology,the inhibition of hepatogenic AGT has shown a good clinical prospect,which can reduce blood pressure continuously and steadily and improve the structure and function of target organs in hypertension.Based on the latest studies,this paper describes the structure and role of AGT gene,the classification of methods for inhibiting hepatogenic AGT,and the effects of inhibiting hepatogenic AGT on RAS molecules,hypertension and target organs,so as to provide a reference for antihypertensive treatment of inhibiting hepatogenic AGT.

关 键 词：血管紧张素原 高血压 反义寡核苷酸 小干扰RNA CRISPR/Cas9 

分 类 号：R554.1[医药卫生—血液循环系统疾病]